Cristina Solé | Biochemistry, Genetics and Molecular Biology | Women Researcher Award

Posted on by ScienceFather

Dr. Cristina Solé | Biochemistry, Genetics and Molecular Biology | Women Researcher Award

Investigadora Principal Sénior-Júnior at Vall Hebron Institut Research VHIR, Spain

Dr. Cristina Solé Marcé is a distinguished researcher specializing in systemic lupus erythematosus (SLE) with over a decade of experience in clinical-translational research. She holds dual degrees in Chemistry and Biochemistry, a PhD with international distinction, and a master’s in Synthesis and Catalysis from Universitat Rovira i Virgili. As a Senior-Junior Principal Investigator at Vall d’Hebron Research Institute, her work focuses on identifying novel biomarkers, developing personalized treatments, and exploring innovative therapies such as CAAR-T cells for lupus nephritis. She has published 31 scientific articles, with 94% as first, last, or corresponding author, and has collaborated with leading institutions, startups, and pharmaceutical companies. A recipient of the 2023 Health Science Award from the Institut d’Estudis Catalans, she is actively engaged in clinical trials, mentorship, and public science outreach. Dr. Solé’s contributions significantly advance lupus research, making her an outstanding candidate for the Women Researcher Award.

Professional Profile 

Education

Dr. Cristina Solé Marcé has a strong academic background in chemistry, biochemistry, and translational medicine. She earned dual degrees in Chemistry and Biochemistry from Universitat Rovira i Virgili, followed by a master’s in Synthesis and Catalysis at the same institution. She later pursued a PhD with international distinction, focusing on innovative research in systemic lupus erythematosus (SLE). Her doctoral work provided a solid foundation for her career in clinical and translational research, particularly in autoimmune diseases. Committed to continuous learning, Dr. Solé has engaged in specialized training programs, including those in biomarker discovery and personalized medicine. Her educational journey, complemented by interdisciplinary expertise and hands-on research, has positioned her as a leading scientist in lupus research. With extensive collaborations and contributions to high-impact publications, her academic achievements continue to shape advancements in precision medicine and novel therapeutic approaches for lupus and related autoimmune disorders.

Professional Experience

Dr. Cristina Solé Marcé is an accomplished researcher specializing in autoimmune diseases, particularly systemic lupus erythematosus (SLE). She has extensive experience in translational and clinical research, focusing on biomarker discovery and personalized medicine. Throughout her career, she has collaborated with leading research institutions and hospitals, contributing to the advancement of novel diagnostic and therapeutic strategies. Dr. Solé has played a key role in multidisciplinary research projects, integrating molecular biology, immunology, and clinical data to improve patient outcomes. She has also published extensively in high-impact scientific journals and presented her findings at international conferences. Her expertise extends to project management, mentorship of young researchers, and securing competitive research funding. Currently, she continues to drive innovation in lupus research, leveraging her knowledge in precision medicine to develop targeted treatments. Her work has had a significant impact on improving the understanding and management of autoimmune diseases worldwide.

Research Interest

Dr. Cristina Solé Marcé’s research interests focus on autoimmune diseases, with a particular emphasis on systemic lupus erythematosus (SLE). Her work explores the molecular mechanisms underlying disease pathogenesis, aiming to identify novel biomarkers for early diagnosis, prognosis, and treatment response. She is deeply involved in translational research, integrating clinical data with advanced molecular and immunological techniques to develop personalized therapeutic strategies. Dr. Solé is particularly interested in the role of epigenetics, gene expression, and immune system dysregulation in lupus and related disorders. Her research also extends to precision medicine approaches, seeking to tailor treatments to individual patients based on their genetic and molecular profiles. She collaborates with multidisciplinary teams, including clinicians, bioinformaticians, and immunologists, to translate laboratory discoveries into clinical applications. Through her work, Dr. Solé aims to enhance disease management and improve the quality of life for patients suffering from autoimmune conditions.

Award and Honor

​Dr. Cristina Solé Marcé is a distinguished researcher specializing in autoimmune diseases, particularly systemic lupus erythematosus (SLE) and antiphospholipid syndrome. Since 2021, she has served as a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute (VHIR). Prior to this role, she dedicated six years as a postdoctoral researcher within the same unit. Her research endeavors focus on enhancing patient outcomes by identifying novel biomarkers to monitor disease status non-invasively and exploring the effects of new drugs and molecular pathways involved in various clinical manifestations. This work has led to multiple publications in internationally recognized journals and invitations to present at prestigious conferences such as the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).

Research Skill

Dr. Cristina Solé Marcé possesses a diverse range of research skills, particularly in the fields of autoimmune diseases, biomarker discovery, and drug synthesis. She has extensive experience in molecular biology techniques, biochemical assays, and analytical chemistry, which she applies to her studies on systemic lupus erythematosus (SLE) and antiphospholipid syndrome. Her expertise includes non-invasive biomarker identification to improve disease monitoring and understanding the mechanisms of action of novel therapeutic agents. With a strong background in synthetic chemistry, she has worked on the enantioselective synthesis of drugs and the development of anticancer compounds. Additionally, she is skilled in experimental design, data analysis, and scientific communication, with multiple publications in high-impact journals and presentations at international conferences such as ACR and EULAR. Her interdisciplinary approach, combining chemistry, biochemistry, and immunology, enables her to contribute significantly to translational research and patient-centered advancements in rheumatology.

Conclusion

Dr. Cristina Solé Marcé is a highly accomplished researcher with an impressive track record in autoimmune disease research, particularly lupus. Her combination of scientific excellence, leadership, international collaboration, and patient engagement makes her a compelling candidate for the Women Researcher Award. Strengthening her funding profile and expanding her research applications could further solidify her impact. Given her current achievements, she is well-deserving of recognition through this award.

Publications Top Noted

  • Solé et al., 2025 – Topical miRNA Delivery via Elastic Liposomal Formulation: A Promising Genetic Therapy for Cutaneous Lupus Erythematosus. Int. J. Mol. Sci. DOI: 10.3390/ijms26062641
  • Sandoval, Solé et al., 2024 – Neuropilin-1 as a Key Molecule for Renal Recovery in Lupus Nephritis: Insights from an NZB/W F1 Mouse Model. Int. J. Mol. Sci. DOI: 10.3390/ijms252111364
  • Solé et al., 2024 – Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells. Int. J. Mol. Sci. DOI: 10.3390/ijms25084226
  • Solé et al., 2023 – Small-Extracellular-Vesicle-Derived miRNA Profile Identifies miR-483-3p and miR-326 as Regulators in the Pathogenesis of Antiphospholipid Syndrome (APS). Int. J. Mol. Sci. DOI: 10.3390/ijms241411607
  • Solé et al., 2023 – Downregulation of miR-885-5p Promotes NF-κB Pathway Activation and Immune Recruitment in Cutaneous Lupus Erythematosus. J. Investig. Dermatol. DOI: 10.1016/j.jid.2022.08.036
  • Solé et al., 2022 – Humoral and Cellular Response in Convalescent COVID-19 Lupus Patients. Sci. Rep. DOI: 10.1038/s41598-022-17334-5
  • Domingo, Solé et al., 2021 – Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways. Biomedicines. DOI: 10.3390/biomedicines9121857
  • Domingo, Solé et al., 2020 – Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. Dermatology. DOI: 10.1159/000508672
  • Domingo, Solé et al., 2020 – MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus, and Atopic Dermatitis. Cells. DOI: 10.3390/cells9122656
  • Garcia-Vives, Solé et al., 2020 – The Urinary Exosomal miRNA Expression Profile is Predictive of Clinical Response in Lupus Nephritis. Int. J. Mol. Sci. DOI: 10.3390/ijms21041372
  • Solé et al., 2019 – MicroRNA Expression Profiling Identifies miR-31 and miR-485-3p as Regulators in the Pathogenesis of Discoid Cutaneous Lupus. J. Investig. Dermatol. DOI: 10.1016/j.jid.2018.07.026

Calver Pang | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Dr. Calver Pang | Medicine and Dentistry | Best Researcher Award

Plastic Surgery Registrar at UCL, Division of Surgery & Interventional Science, United Kingdom

Dr. Calver Pang is an accomplished medical researcher and plastic surgery specialist with extensive experience in vascular malformations. He holds a PhD from University College London and has completed a prestigious surgical research fellowship at Johns Hopkins University. With multiple peer-reviewed publications and contributions to systematic reviews, his work has significantly influenced clinical practice, particularly in sclerotherapy and molecular pathogenesis. He has secured over £146,000 in research grants, including funding from The Butterfly AVM Charity and The Royal Free Charity. Recognized with several research awards, including the Qualitative Research Winner (Society of Academic & Research Society, 2020), he has demonstrated a strong commitment to advancing medical science. His multidisciplinary collaborations, spanning vascular and plastic surgery, pharmacology, and nanotechnology, highlight his innovative approach. While further leadership in large-scale trials could strengthen his profile, his impressive research achievements and clinical impact make him a strong contender for the Best Researcher Award.

Professional Profile 

Education

Dr. Calver Pang has a distinguished educational background spanning medicine, surgery, and pharmacology. He earned his MBChB from the University of Leicester in 2015, followed by Membership of the Royal College of Surgeons (MRCS) Edinburgh in 2021. He is currently pursuing a PhD at University College London (UCL), focusing on biomarkers in vascular malformations, demonstrating his commitment to advancing medical research. Additionally, he holds a First-Class Honours MPharm degree from UCL’s School of Pharmacy (2010), showcasing his strong foundation in both medicine and pharmacology. His dedication to medical education is further evident through his Associate Fellowship of the Higher Education Academy (AFHEA, 2021). Beyond formal education, he has completed multiple advanced surgical training courses, including ATLS, CCrISP, and EMSB, enhancing his expertise in trauma, critical care, and reconstructive surgery. His diverse academic qualifications highlight his interdisciplinary expertise, making him a well-rounded and accomplished researcher and clinician.

Professional Experience

Dr. Calver Pang has an extensive and diverse professional background in surgery and medical research. Currently, he is a Specialty Training (ST4) plastic surgery trainee at Cambridge University Hospitals (2024–2025), following his ST3 role in the same department. His expertise spans plastic, vascular, trauma, orthopaedic, and general surgery, having trained at prestigious institutions such as the Royal Free London NHS Foundation Trust, University Hospitals of Leicester, and Addenbrooke’s Hospital. His international experience includes a Surgical Research Fellowship at Johns Hopkins University (2015–2017), where he contributed to cutting-edge research in surgery. Additionally, he served as a Clinical Research Fellow at the Royal Free London NHS Trust (2017–2020), focusing on vascular malformations and gene therapy. His career reflects a strong balance between clinical excellence and research innovation, with leadership in multi-disciplinary studies and numerous high-impact publications. His expertise in both clinical practice and academia makes him a standout in his field.

Research Interest

Mr. Calver Pang’s research interests lie at the intersection of vascular malformations, plastic surgery, and regenerative medicine. His PhD at University College London focuses on the characterization of biomarkers in vascular malformations, aiming to improve diagnostic accuracy and treatment strategies. He has extensively studied embolotherapy, sclerotherapy, and molecular pathogenesis, contributing to advancements in minimally invasive interventions. His work also extends to gene therapy and nanotechnology in wound healing, demonstrating his innovative approach to translational medicine. He has published multiple peer-reviewed articles on mental health and quality of life in patients with congenital vascular disorders, emphasizing holistic patient care. Additionally, his interest in botulinum toxin therapy for vascular conditions showcases his commitment to pioneering new treatments. With a strong foundation in both clinical and laboratory-based research, he continues to explore novel therapies that bridge the gap between basic science and real-world medical applications, ultimately improving patient outcomes.

Award and Honor
Mr. Calver Pang has received numerous awards and honors in recognition of his outstanding contributions to medical research and surgery. He was awarded the Qualitative Research Winner by the Society of Academic & Research Society (2020) and the ASiT Virtual Event Bursary (2020), highlighting his excellence in academic research. He has secured multiple prestigious grants, including The Butterfly AVM Charity Grant (£136,080, 2019) and The Royal Free Charity Grant (£10,000, 2019), supporting his work in vascular malformations. His achievements also include the Robert Brown Travel Award from UCL (2019) and various elective scholarships, such as the British Medical and GlaxoSmithKline Dental Students’ Trust (£800, 2015) and the British Association of Plastic Reconstructive and Aesthetic Surgeons bursary (£500, 2015). His recognition at both national and international levels reflects his dedication to advancing medical science, making him a highly regarded researcher and clinician in his field.

Research Skill

Mr. Calver Pang possesses a diverse and advanced set of research skills, making him a distinguished medical researcher. He is highly proficient in clinical and translational research, with expertise in biomarker analysis, histopathology, and molecular pathogenesis of vascular malformations. His ability to design and conduct systematic reviews, multicenter studies, and observational research has led to numerous high-impact publications. He is skilled in statistical analysis, data interpretation, and research methodology, ensuring rigorous and evidence-based conclusions. His experience in grant writing and securing competitive funding—amounting to over £146,000 in research grants—demonstrates his ability to drive independent research projects. Additionally, he has experience in nanotechnology and gene therapy, applying innovative approaches to wound healing and regenerative medicine. His multidisciplinary collaborations across vascular surgery, plastic surgery, and pharmacology further enhance his research versatility. His analytical mindset and dedication to advancing medical knowledge make him a leading researcher in his field.

Conclusion

Mr. Calver Pang is a highly suitable candidate for the Best Researcher Award, with a strong research background, multiple grants, and impactful publications. His contributions to vascular malformation research and multidisciplinary approach set him apart. While he could further solidify his leadership with larger-scale studies and more high-impact journal publications, his current achievements make him a compelling contender for the award.

Publications Top Noted

  • Author(s): Pang, C., Iakovou, D., Fraser, D., Langridge, B.J., Butler, P.E.M.
  • Year: 2025
  • Title: A systematic review of botulinum toxin as a treatment for Raynaud’s disease secondary to scleroderma
  • Journal: Clinical Rheumatology

Ze-Min Yang | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Prof. Ze-Min Yang | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

College teachers at Guangdong Pharmaceutical University, China

Professor Ze-Min Yang is a distinguished researcher specializing in metabolic disease pathogenesis and pharmacological research integrating Traditional Chinese Medicine (TCM) with Western medicine. With over 40 academic publications, including 13 SCI-indexed papers, and three invention patents, he has made significant contributions to biomedical research. He has led multiple prestigious projects, including National Natural Science Foundation grants and provincial research collaborations, demonstrating strong leadership and innovation. Serving as Deputy Director at Guangdong Pharmaceutical University, he plays a key role in academic mentorship and scientific evaluation at the provincial level. His accolades, such as “Outstanding Science and Technology Worker” and “Outstanding Teacher,” further highlight his excellence. While his research output is impressive, enhancing international collaborations, increasing citation impact, and expanding interdisciplinary applications could further strengthen his global recognition. Overall, his achievements and leadership make him a strong candidate for the Best Researcher Award, recognizing his impactful contributions to science and medicine.

Professional Profile 

Education

Professor Ze-Min Yang has a strong academic foundation spanning multiple disciplines. He earned his Ph.D. in 2012 from the Institute of Spleen and Stomach Research at Guangzhou University of Traditional Chinese Medicine, specializing in integrated traditional Chinese and Western medicine clinical practice. Prior to this, he obtained a Master’s degree in Hydrobiology from the Hydrobiology Research Center of Jinan University in 2005, demonstrating his expertise in biological sciences. His academic journey began with a Bachelor’s degree in Freshwater Fisheries from the Department of Fisheries at Southwest Agricultural University in 2002. This diverse educational background has provided him with a unique interdisciplinary perspective, integrating biomedical sciences, traditional medicine, and hydrobiology. His advanced training and research experience have contributed to his expertise in metabolic disease pathogenesis and pharmacological research, reinforcing his position as a leading academic in the field of biomedical and pharmaceutical sciences.

Professional Experience

Professor Ze-Min Yang has an extensive professional background in biomedical and pharmaceutical sciences. He currently serves as a faculty member in the Department of Biochemistry and Molecular Biology at the School of Basic Medical Sciences, Guangdong Pharmaceutical University. Additionally, he holds the position of Deputy Director of the Experimental Teaching Center, where he plays a key role in advancing scientific research and education. His expertise is recognized at the provincial level, as he actively contributes as an expert in science and technology project evaluation and acceptance for both Guangdong Province and Guangzhou City. Throughout his career, he has led multiple prestigious research projects, including those funded by the National Natural Science Foundation and Guangdong Provincial Science and Technology Department. His leadership in academic research, combined with his contributions to scientific evaluation and mentorship, underscores his dedication to advancing biomedical sciences and fostering innovation in traditional Chinese and Western medicine integration.

Research Interest

Professor Ze-Min Yang’s research interests focus on the pathogenesis of metabolic diseases and the pharmacological effects of integrating Traditional Chinese Medicine (TCM) with Western medicine. His work explores innovative approaches to understanding and treating metabolic disorders through a combination of molecular biology, biochemistry, and traditional herbal medicine. He is particularly interested in identifying bioactive compounds in TCM that can be used for drug development and disease management. His interdisciplinary research extends to studying the mechanisms of metabolic regulation, inflammation, and gut microbiota interactions in disease progression. By bridging modern biomedical research with traditional healing practices, he aims to develop novel therapeutic strategies that are both scientifically validated and culturally relevant. His contributions, supported by multiple national and provincial research grants, significantly advance the integration of TCM with evidence-based medicine, enhancing its global recognition and application in modern healthcare.

Award and Honor

Professor Ze-Min Yang has received numerous awards and honors in recognition of his outstanding contributions to scientific research, education, and innovation. He has been honored with titles such as “Outstanding Science and Technology Worker,” “Advanced Teaching Worker,” and “Outstanding Teacher” by Guangdong Pharmaceutical University, reflecting his excellence in both research and academia. His leadership in biomedical sciences and commitment to integrating Traditional Chinese Medicine with Western medicine have earned him prestigious recognition at institutional and provincial levels. Additionally, his contributions as an expert in science and technology project evaluation for Guangdong Province and Guangzhou City highlight his influence in shaping research policies and advancements. With multiple funded projects, over 40 academic publications, and three invention patents, his work has significantly impacted the field of metabolic disease research. These accolades reinforce his reputation as a distinguished scientist and educator, making him a strong candidate for prestigious research awards.

Research Skill

Professor Ze-Min Yang possesses a diverse and advanced set of research skills, particularly in the fields of biochemistry, molecular biology, and pharmacology. His expertise lies in investigating the pathogenesis of metabolic diseases and the therapeutic potential of Traditional Chinese Medicine (TCM) integrated with Western medicine. He has extensive experience in experimental design, data analysis, and clinical applications, allowing him to bridge theoretical research with practical medical solutions. His work involves drug discovery, biomarker identification, and molecular mechanism studies, utilizing cutting-edge laboratory techniques such as cell culture, gene expression analysis, and bioinformatics. Additionally, his ability to lead multi-disciplinary research projects, secure national and provincial funding, and collaborate with experts in biomedical sciences demonstrates his strong project management and leadership skills. His contributions, including over 40 academic publications and three patents, highlight his ability to drive innovative research that advances both scientific knowledge and clinical applications.

Conclusion

Professor Ze-Min Yang is a strong candidate for the Best Researcher Award due to his extensive research in metabolic diseases, leadership in TCM and Western medicine integration, multiple prestigious grants, and significant academic contributions. To further enhance his profile, international collaborations, higher-impact publications, and broader interdisciplinary work would strengthen his candidacy.

Publications Top Noted

  • Title: “Identification of microRNA and analysis of target genes in Panax ginseng”

    Authors: Yingfang Wang, Yanlin Chen, Mengyuan Peng, Yongqin Yin, Yu Zeng

    Year: 2023

    Citations: 8

    Source: Chinese Herbal Medicines

  • Title: “Astragalus Polysaccharides Alleviate Type 2 Diabetic Rats by Reversing the Expressions of Sweet Taste Receptors and Genes Related to Glycolipid Metabolism in Liver”

    Authors: Mengjuan Luo, Ying Wang, Siyu Chen, Zemin Yang

    Year: 2022

    Citations: 14

    Source: Frontiers in Pharmacology

Liying Zhang | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Dr. Liying Zhang | Medicine and Dentistry | Best Researcher Award

Professor at University of California, Los Angeles, United States

Dr. Liying Zhang, MD, PhD, FACMG, is a distinguished researcher and professor specializing in molecular diagnostics and precision oncology. She serves as the Director of the Advanced Molecular Diagnostics Service at UCLA David Geffen School of Medicine and the Director of Cancer Molecular Diagnostics at UCLA Jonsson Comprehensive Cancer Center. With extensive experience in molecular genetics, her research focuses on cancer diagnostics, biomarker discovery, and precision medicine. She has contributed to numerous high-impact studies, secured significant research funding, and played an active role in national and international expert committees. Her expertise spans clinical molecular genetics, genomics, bioinformatics, and laboratory medicine, making her a leading figure in the field of cancer molecular diagnostics.

Professional Profile 

Education

Dr. Zhang earned her Ph.D. in Biochemistry and Molecular Biology from The Johns Hopkins University in 2003, alongside a Master’s degree in Computer Science with a focus on Bioinformatics in 2002. She obtained her MD from Peking University, Beijing, China, in 1994. She holds multiple clinical licensures and board certifications, including Clinical Molecular Genetics and Genomics from the American Board of Medical Genetics and Genomics. Her strong educational foundation in medicine, biochemistry, molecular biology, and computational science has equipped her with the interdisciplinary expertise required for advancing molecular diagnostics and precision medicine.

Professional Experience

Dr. Zhang has held several prestigious roles in molecular pathology and diagnostics. Since 2020, she has been a Professor and Director at UCLA, leading advanced molecular diagnostics initiatives. Previously, she served as a Director and Molecular Geneticist at Memorial Sloan Kettering Cancer Center from 2005 to 2019, overseeing diagnostic molecular genetics laboratories and contributing to groundbreaking cancer research. Her earlier roles include research positions at the National Research Institute for Family Planning in China. Additionally, she has been actively involved in professional committees, journal reviews, and mentorship programs, furthering advancements in molecular diagnostics and genetic research.

Research Interest

Dr. Liying Zhang’s research focuses on molecular diagnostics, cancer genomics, and precision oncology. She is dedicated to identifying genetic biomarkers that enhance cancer detection, prognosis, and treatment strategies. Her work involves integrating next-generation sequencing (NGS) technologies, bioinformatics, and molecular pathology to improve the accuracy and efficiency of cancer diagnostics. She is particularly interested in the molecular mechanisms underlying tumor development, drug resistance, and targeted therapies. Through collaborations with oncologists, geneticists, and data scientists, she aims to translate genetic findings into clinically actionable insights that improve patient outcomes. Her research also extends to liquid biopsy, epigenetics, and the development of novel molecular assays for early cancer detection.

Awards and Honors

Dr. Zhang has received numerous prestigious awards recognizing her contributions to molecular genetics and cancer diagnostics. She has been honored as a Fellow of the American College of Medical Genetics and Genomics (FACMG), acknowledging her leadership and expertise in clinical molecular genetics. She has also received research excellence awards from institutions such as Memorial Sloan Kettering Cancer Center and UCLA for her groundbreaking work in cancer molecular diagnostics. Additionally, she has been an invited speaker at leading international conferences, including the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP). Her contributions to scientific research and clinical practice have earned her recognition as a thought leader in precision medicine and molecular oncology.

Research Skills

Dr. Zhang possesses a diverse range of research skills in molecular diagnostics and genomics. She is proficient in next-generation sequencing (NGS) technologies, whole-genome and transcriptome analysis, and single-cell sequencing. She has extensive experience in bioinformatics, data mining, and computational modeling for genetic variant interpretation. Her expertise includes designing and validating molecular assays for clinical diagnostics, including PCR-based and hybrid capture-based sequencing methods. She is also skilled in laboratory management, regulatory compliance, and quality control in clinical molecular genetics laboratories. Additionally, her strong background in translational research allows her to bridge the gap between basic scientific discoveries and clinical applications, ensuring that her findings have a direct impact on patient care and personalized treatment strategies.

Conclusion

Dr. Liying Zhang is highly suitable for the Best Researcher Award due to her exceptional contributions to molecular diagnostics, cancer genomics, and precision medicine. Her extensive experience in research leadership, grant acquisition, and clinical applications makes her an outstanding candidate. Strengthening her independent research leadership and international collaborations would further solidify her candidacy for this prestigious award.

Publications Top Noted

  • Title: Inherited DNA-repair gene mutations in men with metastatic prostate cancer
    Authors: CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, …
    Year: 2016
    Citation: 1765

  • Title: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
    Authors: L Klotz, L Zhang, A Lam, R Nam, A Mamedov, A Loblaw
    Year: 2010
    Citation: 1402

  • Title: Long-term follow-up of a large active surveillance cohort of patients with prostate cancer
    Authors: L Klotz, D Vesprini, P Sethukavalan, V Jethava, L Zhang, S Jain, …
    Year: 2015
    Citation: 1399

  • Title: CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct
    Authors: IYL Tan, AM Demchuk, J Hopyan, L Zhang, D Gladstone, K Wong, …
    Year: 2009
    Citation: 792

  • Title: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Authors: J Holzbeierlein, P Lal, E LaTulippe, A Smith, J Satagopan, L Zhang, …
    Year: 2004
    Citation: 708

  • Title: Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer
    Authors: A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, …
    Year: 2019
    Citation: 591

  • Title: Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Authors: W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, …
    Year: 2017
    Citation: 583

  • Title: Celiac disease: summary
    Authors: A Rostom, C Dubé, A Cranney, N Saloojee, R Sy, C Garritty, M Sampson, …
    Year: 2004
    Citation: 511

  • Title: Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing
    Authors: D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, …
    Year: 2017
    Citation: 508

  • Title: Tumour lineage shapes BRCA-mediated phenotypes
    Authors: P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, …
    Year: 2019
    Citation: 384

  • Title: Hereditary diffuse gastric cancer: updated clinical practice guidelines
    Authors: VR Blair, M McLeod, F Carneiro, DG Coit, JL D’Addario, JM van Dieren, …
    Year: 2020
    Citation: 381

  • Title: Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases
    Authors: E Chow, P Hoskin, G Mitera, L Zeng, S Lutz, D Roos, C Hahn, …
    Year: 2012
    Citation: 374

  • Title: Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data
    Authors: S Middha, L Zhang, K Nafa, G Jayakumaran, D Wong, HR Kim, …
    Year: 2017
    Citation: 363

  • Title: Genetic predictors of response to systemic therapy in esophagogastric cancer
    Authors: YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, …
    Year: 2018
    Citation: 352

Ahmet Altay | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Ahmet Altay | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Erzincan Üniversitesi, Turkey

Dr. Ahmet Altay is an accomplished researcher and academic in the field of chemistry, specializing in biochemistry, medicinal chemistry, and interdisciplinary sciences. With a strong background in natural product chemistry and anticancer drug discovery, he has contributed significantly to the scientific community through his research on antioxidants, cytotoxic agents, and enzyme inhibition. His extensive publication record in high-impact SCI-Expanded journals highlights his expertise in experimental and computational studies. Currently serving as an Associate Professor at Erzincan Binali Yıldırım University, Dr. Altay continues to push the boundaries of chemical and biochemical research, focusing on novel therapeutic compounds and their biological applications.

Professional Profile 

Education

Dr. Ahmet Altay earned his Ph.D. in Biochemistry from Middle East Technical University (METU), Turkey, in 2015. His doctoral research focused on the antioxidant and cytotoxic properties of Salvia fruticosa M., as well as its effects on cytochrome P450 enzymes and antioxidant gene expression in colon cancer cells.

Professional Experience

Dr. Altay has been a faculty member at Erzincan Binali Yıldırım University since 2016. He started as an Assistant Professor (2016-2018), was promoted to Associate Professor in 2020, and has since been actively involved in research and teaching. His work spans multiple disciplines within chemistry and biochemistry, with a strong focus on drug discovery and molecular interactions. His contributions include supervising graduate students, securing research grants, and collaborating on international scientific projects.

Research Interests

Dr. Ahmet Altay’s research interests lie at the intersection of biochemistry, medicinal chemistry, and pharmacology, with a particular focus on drug discovery and natural product chemistry. His work extensively explores the antioxidant, anticancer, and enzyme-inhibitory properties of bioactive compounds derived from medicinal plants. He is also deeply engaged in molecular docking studies to understand drug-receptor interactions at a computational level. Additionally, his research investigates apoptosis mechanisms, oxidative stress-related disorders, and the modulation of key metabolic pathways in cancer and neurodegenerative diseases. By integrating experimental and computational approaches, Dr. Altay aims to develop novel therapeutic agents that can target cancer, microbial infections, and enzyme-related disorders. His interdisciplinary research combines chemical synthesis, molecular modeling, and pharmacological evaluation to provide innovative solutions in biomedical sciences.

Awards and Honors

Dr. Ahmet Altay has received multiple awards and recognitions for his outstanding contributions to scientific research and academia. His excellence in publishing high-impact research has been acknowledged with best paper awards and recognitions from international conferences and scientific organizations. He has been honored with research grants and funding support for his projects on natural product chemistry and drug discovery. As an active academic, he has also received accolades for his contributions to student mentorship and scientific collaboration. His efforts in cancer research and enzyme inhibition studies have been recognized by national and international institutions. Additionally, his role as a peer reviewer and editorial board member in prestigious scientific journals highlights his expertise and influence in the field. These awards and honors underscore his dedication to advancing biomedical and pharmaceutical sciences.

Research Skills

Dr. Ahmet Altay possesses a diverse set of research skills spanning experimental and computational methodologies. His expertise includes the isolation and structural characterization of bioactive natural products using advanced chromatographic and spectroscopic techniques such as HPLC, GC-MS, and NMR. He is highly proficient in molecular docking, molecular dynamics simulations, and in silico drug design to predict ligand-target interactions. His skills in biochemical assays enable the evaluation of antioxidant, antimicrobial, and anticancer activities of synthetic and natural compounds. Additionally, he has extensive experience in enzyme kinetics, apoptosis studies, and gene expression analysis using RT-PCR and Western blot techniques. His interdisciplinary knowledge allows him to integrate synthetic chemistry, pharmacology, and bioinformatics to address complex biomedical challenges. Dr. Altay’s strong analytical skills, coupled with his experience in mentoring and collaboration, make him a leading researcher in his field.

Conclusion

Dr. Ahmet Altay is a strong candidate for the Best Researcher Award due to his high research output, international collaborations, and contributions to anticancer and biochemical research. To enhance his profile further, he could focus on leading large-scale projects, securing more grants, and publishing in top-tier journals. Nonetheless, his achievements make him a compelling nominee for this award.

Publications Top Noted

  • Title: Diffractaic acid exerts anti-cancer effects on hepatocellular carcinoma HepG2 cells by inducing apoptosis and suppressing migration through targeting thioredoxin reductase 1

    • Authors: Emine Karaca Sulukoğlu, Şükran Günaydın, Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2024
    • Citation: Naunyn-Schmiedeberg’s Archives of Pharmacology
    • DOI: 10.1007/s00210-024-02980-5

  • Title: The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

    • Authors: Esma Kübra Kağan Yeniçeri, Ahmet Altay
    • Year: 2024
    • Citation: Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
    • DOI: 10.18185/erzifbed.1376859

  • Title: Diffractaic acid exhibits thioredoxin reductase 1 inhibition in lung cancer A549 cells

    • Authors: Şükran Günaydın, Emine Karaca Sulukoğlu, Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2023
    • Citation: Journal of Applied Toxicology
    • DOI: 10.1002/jat.4505

  • Title: Effect of evernic acid on human breast cancer MCF‐7 and MDA‐MB‐453 cell lines via thioredoxin reductase 1: A molecular approach

    • Authors: Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2023
    • Citation: Journal of Applied Toxicology
    • DOI: 10.1002/jat.4451

  • Title: In Vitro Cytotoxic Evaluation of a Silver(I) Complex Including Non-Steroidal Anti-Inflammatory Drug Niflumic Acid and 3-Picoline on Human-Derived Cancer Cell Lines

    • Authors: Sema Çağlar, Ahmet Altay, Bülent Çağlar, Esma Kübra Kağan Yeniçeri, Betül Harurluoğlu
    • Year: 2022
    • Citation: Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
    • DOI: 10.18185/erzifbed.1130634

  • Title: A Biochemical Approach for Hedysarum candidissimum from Turkey: Screening Phytochemicals, Evaluation of Biological Activities, and Molecular Docking Study

    • Authors: Ahmet Altay, Esma Yeniceri, Parham Taslimi, Tugba Taskin‐Tok, Mustafa Abdullah Yilmaz, Ekrem Koksal
    • Year: 2022
    • Citation: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202200348

  • Title: Phytochemical Analysis and Biological Evaluation of Hypericum linarioides Bosse: in Vitro and in Silico Studies

    • Authors: Ahmet Altay, Esma Kübra Kağan Yeniçeri, Parham Taslimi, Tugba Taskin‐Tok, Mustafa Abdullah Yılmaz, Ekrem Köksal
    • Year: 2022
    • Citation: ChemistrySelect
    • DOI: 10.1002/slct.202200039

Kannan Pandian | Agricultural and Biological Sciences | Best Researcher Award

Posted on by ScienceFather

Dr. Kannan Pandian | Agricultural and Biological Sciences | Best Researcher Award

Associate Professor at Tamil Nadu Agricultural University, India

Dr. Kannan Pandian is an accomplished researcher in Soil Science and Agricultural Chemistry with expertise in dryland soil resource management, carbon sequestration, and nutrient efficiency enhancement. His research focuses on combating climate vulnerability through carbon and water conservation techniques and developing eco-friendly fertilizers for sustainable agriculture. With over 56 peer-reviewed journal articles, 8 books, 16 book chapters, and two granted patents, he has significantly contributed to soil health, plant nutrition, and precision farming. He has received multiple prestigious awards, including the ICAR-IDP International Faculty Training Fellowship and the Best TNAU Young Scientist Award. His work has been widely recognized at national and international levels, with projects funded by ICAR, DST, and the Tamil Nadu State Development Council.

Professional Profile 

Education

Dr. Kannan Pandian earned his Ph.D. in Soil Science and Agricultural Chemistry from Tamil Nadu Agricultural University (TNAU), Coimbatore, India, in 2007. He completed his Master of Science in the same field from TNAU in 2004 and obtained his Bachelor of Science in Agriculture from TNAU in 2002. His academic journey was marked by excellence, earning several awards, including the Dr. K.K. Krishnamurthy and Dr. G. Selvakumari Medal for Best Doctoral Student and the Prof. T. Balakrishnan Medal for Best Master’s Student. Additionally, he was a recipient of the NADP-RKVY Soil Health Research Fellowship and the Krishnamoorthy International Agricultural Development Foundation Scholarship, highlighting his academic and research proficiency.

Professional Experience

Dr. Kannan Pandian currently serves as an Associate Professor at the Department of Soils and Environment, Tamil Nadu Agricultural University (TNAU). Previously, he held positions as an Assistant Professor at TNAU, a Scientist at the Indian Council of Agricultural Research (ICAR), a Research Associate at the Centre for Soil and Crop Management Studies (CSCMS), and a Senior Research Fellow at TNAU. His research focuses on developing organo-mineral biochar, electrochemical sensor-based soil nutrient assessment, and drought-proofing technologies for rainfed agriculture. He has led multiple externally funded projects, collaborated with premier research institutes, and contributed to significant advancements in soil health management. As a peer reviewer for leading journals and an active member of professional societies, he continues to influence agricultural and biological sciences through his research, innovation, and academic contributions.

Research Interests

Dr. Kannan Pandian’s research primarily focuses on soil health management, carbon sequestration, and nutrient efficiency enhancement to improve agricultural sustainability. His work aims to develop climate-resilient farming techniques, emphasizing biochar technology, drought-proofing methods, and eco-friendly fertilizers. He specializes in dryland soil resource management, precision farming, and electrochemical sensor-based soil nutrient assessment. His studies contribute to mitigating climate change impacts by integrating carbon and water conservation strategies in agroecosystems. Additionally, he explores the role of microbial interactions in soil fertility and plant nutrition, leading to the development of innovative soil amendments. His interdisciplinary research combines soil science, environmental chemistry, and precision agriculture to enhance productivity while ensuring ecological balance. Through collaborations with research institutions and agribusiness sectors, he continuously works towards developing sustainable agricultural practices that can be widely adopted in both rainfed and irrigated farming systems.

Awards and Honors

Dr. Kannan Pandian has received numerous prestigious awards and honors in recognition of his contributions to soil science and sustainable agriculture. He was honored with the Best Young Scientist Award by Tamil Nadu Agricultural University (TNAU) for his innovative work on climate-resilient soil management. His research excellence was further acknowledged with the ICAR-IDP International Faculty Training Fellowship, allowing him to conduct advanced studies at Western Sydney University, Australia. He has also been awarded the Dr. APJ Abdul Kalam Best Teacher Award for his exceptional mentorship and academic contributions. His research papers have received Best Paper and Best Presentation Awards at national and international conferences. Additionally, he holds two granted patents for groundbreaking developments in soil health improvement and precision farming. These accolades underscore his pioneering role in agricultural research, driving innovation and sustainability in the field of soil science.

Research Skills

Dr. Kannan Pandian possesses advanced research skills in soil chemistry, agronomic biochar development, and precision agriculture. He is proficient in electrochemical sensor technology for real-time soil nutrient assessment, enabling accurate and efficient fertilizer application. His expertise in carbon sequestration and climate-smart agriculture allows him to develop strategies for mitigating greenhouse gas emissions in farmlands. He is skilled in GIS-based soil mapping, facilitating spatial analysis of soil properties for better land management. His analytical skills extend to soil fertility modeling, microbial interaction studies, and nutrient cycling research. He is experienced in leading multi-institutional research projects, collaborating with international and national organizations to enhance soil and plant health. His technical proficiency in experimental design, statistical data analysis, and field trials strengthens his research outcomes. His ability to integrate traditional soil science with modern precision technologies makes him a leader in sustainable agriculture and soil conservation research.

Conclusion

Dr. Kannan Pandian is an exceptional candidate for the Best Researcher Award, given his extensive contributions to soil science, sustainable agriculture, and climate resilience. His track record in research, innovation, funding, and academic mentorship makes him a strong contender. Strengthening international collaborations, industry partnerships, and patent commercialization would further elevate his global impact.

Publications Top Noted

  • Towards an operational SAR-based rice monitoring system in Asia: Examples from 13 demonstration sites across Asia in the RIICE project
    Authors: A Nelson, T Setiyono, AB Rala, ED Quicho, JV Raviz, PJ Abonete, …
    Year: 2014
    Citations: 197

  • Effect of biochar amendment on soil physical, chemical and biological properties and groundnut yield in rainfed Alfisol of semi-arid tropics
    Authors: K Pandian, P Subramaniayan, P Gnasekaran, S Chitraputhirapillai
    Year: 2016
    Citations: 178

  • Zinc deficiency in Indian soils with special focus to enrich zinc in peanut
    Authors: P Arunachalam, P Kannan, G Prabukumar, M Govindaraj
    Year: 2013
    Citations: 99

  • Biochar from green waste for phosphate removal with subsequent disposal
    Authors: DK Veni, P Kannan, TNJI Edison, A Senthilkumar
    Year: 2017
    Citations: 94

  • Biological properties of soil as influenced by different organic manures
    Authors: P Kannan, A Saravanan, S Krishnakumar, SK Natarajan
    Year: 2005
    Citations: 82

  • Applying both biochar and phosphobacteria enhances Vigna mungo L. growth and yield in acid soils by increasing soil pH, moisture content, microbial growth and P availability
    Authors: P Kannan, M Paramasivan, S Marimuthu, C Swaminathan, J Bose
    Year: 2021
    Citations: 73

  • Drought assessment and monitoring through remote sensing and GIS in western tracts of Tamil Nadu, India
    Authors: D Muthumanickam, P Kannan, R Kumaraperumal, S Natarajan, …
    Year: 2011
    Citations: 57

  • Organic farming on tomato yield and quality
    Authors: P Kannan, A Saravanan, T Balaji
    Year: 2006
    Citations: 57

  • Rice crop monitoring and yield estimation through COSMO Skymed and TerraSAR-X: A SAR-based experience in India
    Authors: S Pazhanivelan, P Kannan, P Christy Nirmala Mary, E Subramanian, …
    Year: 2015
    Citations: 38

  • Implication of micronutrients in agriculture and health with special reference to iron and zinc
    Authors: M Govindaraj, P Kannan, P Arunachalam
    Year: 2011
    Citations: 36

Laura Brannelly | Agricultural and Biological Sciences | Best Researcher Award

Posted on by ScienceFather

Dr. Laura Brannelly | Agricultural and Biological Sciences | Best Researcher Award

Senior Lecturer at University of Melbourne, Australia

Dr. Laura A. Brannelly is a Senior Lecturer in One Health and Biostatistics at the University of Melbourne’s Veterinary School, specializing in disease ecology, amphibian conservation, and the impacts of climate change on wildlife health. She earned her Ph.D. in Public Health, Medical, and Veterinary Sciences from James Cook University, focusing on chytridiomycosis in frogs. Her extensive research experience includes postdoctoral positions funded by the U.S. Department of Defense and the Australian Research Council, investigating amphibian reproduction, pathogen susceptibility, and environmental stressors. Dr. Brannelly is highly skilled in molecular biology, statistical modeling, ecological monitoring, and laboratory infection trials. She has mentored numerous graduate students and coordinated courses in research methods and conservation science. A sought-after speaker, she has presented her work internationally, contributing significantly to wildlife disease management and ecological research. Her work bridges scientific discovery and conservation, addressing pressing global challenges in biodiversity and environmental health.

Professional Profile

Education

Dr. Laura A. Brannelly holds a Ph.D. in Public Health, Medical, and Veterinary Sciences from James Cook University, where she focused on the effects of chytridiomycosis on amphibian populations. Prior to her doctoral studies, she earned a Bachelor of Science degree in Ecology and Evolutionary Biology from the University of Colorado Boulder. Her academic journey has been marked by a strong interdisciplinary approach, integrating ecology, disease dynamics, and conservation biology. During her Ph.D., she conducted extensive field and laboratory research on amphibian disease ecology, contributing valuable insights into wildlife health. Following her doctorate, she pursued postdoctoral research funded by the U.S. Department of Defense and the Australian Research Council, further refining her expertise in epidemiology, ecological modeling, and conservation strategies. Her educational background has provided her with a solid foundation in biostatistics, molecular biology, and ecological monitoring, shaping her career as a leading researcher in wildlife disease ecology.

Professional Experience

Dr. Laura A. Brannelly is a distinguished researcher specializing in wildlife disease ecology, with extensive experience in academia and scientific research. She has held research and faculty positions at leading institutions, including the University of Melbourne, where she investigates amphibian disease dynamics and conservation strategies. Her professional journey includes postdoctoral research funded by the U.S. Department of Defense and the Australian Research Council, focusing on the epidemiology of chytridiomycosis in amphibian populations. She has conducted field research in Australia, Central America, and the United States, collaborating with conservation organizations and government agencies to develop strategies for mitigating disease impacts on biodiversity. Dr. Brannelly is also an active mentor, supervising graduate students and contributing to curriculum development in ecological and veterinary sciences. Her work integrates molecular biology, epidemiology, and ecological modeling to advance conservation efforts and inform policy decisions on wildlife health management globally.

Research Interest

Dr. Laura A. Brannelly’s research focuses on wildlife disease ecology, with a particular emphasis on amphibian health and conservation. She investigates the epidemiology and impact of infectious diseases, such as chytridiomycosis, on amphibian populations worldwide. Her work integrates field studies, laboratory experiments, and ecological modeling to understand disease transmission, host-pathogen interactions, and the environmental factors influencing outbreaks. Dr. Brannelly is especially interested in how amphibian immune responses and life history traits affect disease susceptibility and recovery. She also explores conservation strategies, including disease mitigation, captive breeding programs, and habitat management, to support declining species. By collaborating with global conservation organizations and governmental agencies, she contributes to policies aimed at protecting biodiversity. Her interdisciplinary approach bridges ecology, immunology, and microbiology, providing critical insights into wildlife disease dynamics and informing effective conservation interventions for threatened species.

Research Skill

Dr. Laura A. Brannelly possesses a diverse set of research skills focused on disease ecology, amphibian conservation, and wildlife health. She is highly skilled in experimental design, fieldwork, and laboratory techniques, particularly in studying amphibian disease dynamics, host-pathogen interactions, and conservation interventions. Her expertise includes molecular diagnostics, histopathology, and microbiome analysis to investigate the effects of fungal pathogens such as Batrachochytrium dendrobatidis (chytrid fungus) on amphibian populations. Dr. Brannelly is proficient in statistical modeling and data analysis, employing advanced ecological and epidemiological modeling techniques to assess disease impacts and predict population trends. She is also adept at designing and implementing conservation management strategies, collaborating with governmental and non-governmental organizations to develop effective interventions. Additionally, her strong communication and public engagement skills allow her to translate complex scientific findings into actionable conservation policies. Her multidisciplinary research approach contributes significantly to amphibian conservation and global efforts to mitigate wildlife diseases.

Conclusion

Dr. Laura A. Brannelly is highly suitable for the Best Researcher Award, given her exceptional research track record, leadership, and contributions to disease ecology and amphibian conservation. Minor improvements in research dissemination and interdisciplinary collaborations could further elevate her profile.

Publications Top Noted

  • Title: Chytrid fungus Batrachochytrium dendrobatidis has nonamphibian hosts and releases chemicals that cause pathology in the absence of infection
    Authors: TA McMahon, LA Brannelly, MWH Chatfield, PTJ Johnson, MB Joseph, …
    Year: 2013
    Citations: 262

  • Title: Susceptibility of amphibians to chytridiomycosis is associated with MHC class II conformation
    Authors: A Bataille, SD Cashins, L Grogan, LF Skerratt, D Hunter, M McFadden, …
    Year: 2015
    Citations: 173

  • Title: After the epidemic: ongoing declines, stabilizations and recoveries in amphibians afflicted by chytridiomycosis
    Authors: BC Scheele, LF Skerratt, LF Grogan, DA Hunter, N Clemann, …
    Year: 2017
    Citations: 153

  • Title: Low impact of chytridiomycosis on frog recruitment enables persistence in refuges despite high adult mortality
    Authors: BC Scheele, DA Hunter, LF Skerratt, LA Brannelly, DA Driscoll
    Year: 2015
    Citations: 101

  • Title: Priorities for management of chytridiomycosis in Australia: saving frogs from extinction
    Authors: LF Skerratt, L Berger, N Clemann, DA Hunter, G Marantelli, DA Newell, …
    Year: 2016
    Citations: 98

  • Title: Clinical trials with itraconazole as a treatment for chytrid fungal infections in amphibians
    Authors: LA Brannelly, CL Richards-Zawacki, AP Pessier
    Year: 2012
    Citations: 93

  • Title: A review of the role of parasites in the ecology of reptiles and amphibians
    Authors: DS Bower, LA Brannelly, CA McDonald, RJ Webb, SE Greenspan, …
    Year: 2019
    Citations: 92

  • Title: Reservoir‐host amplification of disease impact in an endangered amphibian
    Authors: BC Scheele, DA Hunter, LA Brannelly, LF Skerratt, DA Driscoll
    Year: 2017
    Citations: 91

  • Title: Amphibians with infectious disease increase their reproductive effort: evidence for the terminal investment hypothesis
    Authors: LA Brannelly, R Webb, LF Skerratt, L Berger
    Year: 2016
    Citations: 69

  • Title: Batrachochytrium dendrobatidis in natural and farmed Louisiana crayfish populations: prevalence and implications
    Authors: LA Brannelly, TA McMahon, M Hinton, D Lenger, CL Richards-Zawacki
    Year: 2015
    Citations: 69

Mohsen Mehrabi | Pharmacology | Excellence in Academic-Industry Collaboration Award

Posted on by ScienceFather

Assist. Prof. Dr.Mohsen Mehrabi | Pharmacology | Excellence in Academic-Industry Collaboration Award

Assistant Professor of Medical Nanotechnology at Shahroud University of Medical Sciences, Iran

Dr. Mohsen Mehrabi is an Assistant Professor of Medical Nanotechnology at Shahroud University of Medical Sciences, with a Ph.D. in Medical Nanotechnology from Tehran University of Medical Sciences. His research focuses on drug and vaccine delivery systems, nanoparticles for wound healing, and nanofiber-based wound dressings. He has published extensively in high-impact journals, contributing significantly to biomedical advancements, particularly in chitosan-based vaccine delivery, essential oil nanoemulsions, and cancer therapies. With expertise in polymeric nanoparticles, niosomes, and phytosomes, his work bridges fundamental research and practical medical applications. Additionally, he holds an MBA in Strategic Management, enhancing his ability to lead interdisciplinary projects. Despite his strong academic record, increased international collaborations, patents, and industry partnerships could further amplify his impact. Dr. Mehrabi’s dedication to innovation in nanomedicine and consistent research output make him a strong candidate for the Best Researcher Award, recognizing his contributions to advancing medical sciences

Professional Profile 

Education

Dr. Mohsen Mehrabi has a diverse and multidisciplinary educational background in medical sciences and nanotechnology. He earned his Ph.D. in Medical Nanotechnology from the School of Advanced Medical Technology at Tehran University of Medical Sciences (2012-2018), where he specialized in nanoparticle-based vaccine delivery systems. Prior to that, he completed his M.Sc. in Medical Nanotechnology at the same institution (2008-2011), focusing on chitosan nanoparticles for drug delivery. He also pursued an MBA in Strategic Management at Tehran University (2021-2022), enhancing his expertise in research leadership and project management. His undergraduate education includes a B.Sc. in Medical Laboratory Sciences from Jondi Shapour Medical University of Ahvaz (2005-2007) and an Associate Degree in Medical Laboratory Sciences from Shiraz University of Medical Sciences (2001-2003). His strong academic foundation in nanomedicine, biotechnology, and medical sciences has significantly contributed to his research in drug delivery, vaccine development, and biomedical applications.

Professional Experience

Dr. Mohsen Mehrabi is an Assistant Professor of Medical Nanotechnology at the School of Medicine, Shahroud University of Medical Sciences (2018–present). With expertise in nanomedicine, drug delivery systems, and biomedical applications, he has played a key role in advancing research on nanoparticle-based drug and vaccine delivery, wound healing, and cancer therapies. His professional journey includes extensive academic research, supervision of scientific projects, and collaboration with international experts in the field of nanotechnology. His work on polymeric nanoparticles, niosomes, phytosomes, and hydrogel-based wound dressings has led to multiple high-impact publications. Additionally, his MBA in Strategic Management has equipped him with leadership and project management skills, allowing him to contribute to research strategy and innovation. Dr. Mehrabi’s dedication to interdisciplinary research and translational science has positioned him as a leading figure in medical nanotechnology, making significant contributions to both academic and applied biomedical research.

Research Interest

Dr. Mohsen Mehrabi’s research interests focus on nanotechnology-driven solutions for drug and vaccine delivery, wound healing, and biomedical applications. His work primarily explores polymeric nanoparticles (chitosan and alginate), niosomes, and phytosomes for targeted drug and vaccine delivery systems, aiming to enhance therapeutic efficacy and immunogenicity. He is particularly interested in the development of nanoparticle-based vaccine carriers, including chitosan-loaded recombinant hepatitis B antigen, to improve immune response. His research extends to essential oil nanoemulsions for antimicrobial and therapeutic applications in both human and veterinary medicine. Additionally, he investigates hydrogel-based nanoparticles for wound healing and nanofiber mesh as advanced wound dressings. His interdisciplinary approach integrates nanomedicine, biotechnology, and pharmaceutical sciences to develop innovative and efficient drug delivery systems. Through his work, Dr. Mehrabi aims to bridge the gap between fundamental nanoscience and clinical applications, contributing to advancements in precision medicine and targeted therapies.

Award and Honor

There is no specific information provided about awards and honors received by Dr. Mohsen Mehrabi. However, given his significant contributions to the field of medical nanotechnology, his extensive research on drug and vaccine delivery systems, and his numerous high-impact publications, he is a strong candidate for academic recognition and prestigious research awards. His work on chitosan-based nanoparticles, essential oil nanoemulsions, and hydrogel-based wound dressings has advanced biomedical applications, making a notable impact in nanomedicine and biotechnology. Additionally, his leadership in interdisciplinary research and his role as an Assistant Professor at Shahroud University of Medical Sciences further highlight his academic excellence. While specific accolades are not listed, his dedication, innovation, and contributions to medical sciences make him a potential recipient of awards recognizing excellence in nanotechnology, drug delivery, and vaccine research. Further details on awards and honors could strengthen his professional profile.

Research Skill

Dr. Mohsen Mehrabi possesses advanced research skills in medical nanotechnology, drug delivery systems, and biomedical applications. His expertise includes the design, synthesis, and characterization of polymeric nanoparticles such as chitosan, alginate, niosomes, and phytosomes for targeted drug and vaccine delivery. He has extensive experience in nanoparticle formulation, stability assessment, and in vitro/in vivo evaluation of drug-loaded systems. His skills extend to hydrogel-based wound dressings, nanofiber mesh fabrication, and essential oil nanoemulsions for therapeutic applications. He is proficient in physicochemical characterization techniques, including spectroscopy, electron microscopy, and chromatographic methods, to analyze nanoparticle properties and drug release profiles. His ability to integrate nanotechnology, immunology, and pharmaceutical sciences enables him to develop novel therapeutic strategies. Additionally, his strategic research planning and project management skills, supported by his MBA in Strategic Management, enhance his ability to lead interdisciplinary studies and contribute to cutting-edge innovations in nanomedicine.

Conclusion

Dr. Mohsen Mehrabi has a remarkable research record in nanomedicine and drug delivery, making him a strong contender for the Best Researcher Award. His work has significant scientific merit, real-world medical applications, and global relevance. Strengthening industry collaborations, patenting innovations, and increasing international leadership roles could further solidify his candidacy.

Publications Top Noted

  1. Title: Comparison of the protective effects of CS/TPP and CS/HPMCP nanoparticles containing berberine in ethanol-induced hepatotoxicity in rat

    • Authors: Mahboubi Kancha M., Alizadeh M., Mehrabi M.
    • Year: 2024
    • Citation: 2

  2. Title: Isolation and Characterization of Extracellular Vesicles of Chick Embryo Blood

    • Authors: Rezakhania L., Gharibshahian M., Zamani S., Mehrabi M., Alizadeh M.
    • Year: 2024
    • Citation: 1

 

 

You said:
Craft compelling and forward-looking web content for the ‘Pharmacology’ Begin with a very short introduction and very short